Journal article icon

Journal article

Identification of novel HIV-1-derived HLA-E-binding peptides

Abstract:
Non-classical class Ib MHC-E molecule is becoming an increasingly interesting component of the immune response. It is involved in both the adaptive and innate immune responses to several chronic infections including HIV-1 and, under very specific circumstances, likely mediated a unique vaccine protection of rhesus macaques against pathogenic SIV challenge. Despite being recently in the spotlight for HIV-1 vaccine development, to date there is only one reported human leukocyte antigen (HLA)-E-binding peptide derived from HIV-1. In an effort to help start understanding the possible functions of HLA-E in HIV-1 infection, we determined novel HLA-E binding peptides derived from HIV-1 Gag, Pol and Vif proteins. These peptides were identified in three independent assays, all quantifying cell-surface stabilization of HLA-E*01:01 or HLA-E*01:03 molecules upon peptide binding, which was detected by HLA-E-specific monoclonal antibody and flow cytometry. Thus, following initial screen of over 400 HIV-1-derived 15-mer peptides, 4 novel 9-mer peptides PM9, RL9, RV9 and TP9 derived from 15-mer binders specifically stabilized surface expression of HLA-E*01:03 on the cell surface in two separate assays and 5 other binding candidates EI9, MD9, NR9, QF9 and YG9 gave a binding signal in only one of the two assays, but not both. Overall, we have expanded the current knowledge of HIV-1-derived target peptides stabilizing HLA-E cell-surface expression from 1 to 5, thus broadening inroads for future studies. This is a small, but significant contribution towards studying the fine mechanisms behind HLA-E actions and their possible use in development of a new kind of vaccines.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1016/j.imlet.2018.08.005

Authors

More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Sub department:
Jenner Institute
Role:
Author
ORCID:
0000-0002-3595-8476
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDM; Target Discovery Institute
Role:
Author
ORCID:
0000-0002-0587-7560


Publisher:
Elsevier
Journal:
Immunology Letters More from this journal
Volume:
202
Pages:
65-72
Publication date:
2018-08-30
Acceptance date:
2018-08-23
DOI:
EISSN:
1879-0542
ISSN:
0165-2478
Pmid:
30172717


Language:
English
Keywords:
Pubs id:
pubs:915392
UUID:
uuid:15d3f57a-8eb0-41b3-a05c-b0c139f58593
Local pid:
pubs:915392
Source identifiers:
915392
Deposit date:
2018-09-25
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP